Re­sis­tant to CAR-T ther­a­pies? It's the can­cer, not your im­mune sys­tem — study

Safe­ty con­cerns and man­u­fac­tur­ing short­com­ings aside, ex­ist­ing CAR-T ther­a­pies — No­var­tis’ Kym­ri­ah and Gilead’s Yescar­ta — sim­ply don’t work in 10% to 20% of pa­tients with B cell ma­lig­nan­cies. What fac­tors un­der­pin this re­sis­tance to CAR-T ther­a­py? The main cul­prit could be the can­cer cells them­selves, ac­cord­ing to a team of re­searchers at Penn.

CAR-T ther­a­pies are en­gi­neered to work in this way: Cells are ex­tract­ed from the pa­tient and then ma­nip­u­lat­ed in a lab where chimeric anti­gen re­cep­tors are added to di­rect the pa­tient’s own T cells to snuff out spe­cif­ic can­cer cells once re-in­fused back in­to the pa­tient. But in a frac­tion of pa­tients, the armed im­mune at­tack does not oblit­er­ate the dis­ease. By tar­get­ing CD19, a mark­er present on al­most all B cells, CAR-T ther­a­pies have shown re­mark­able po­ten­cy and dura­bil­i­ty in a num­ber of blood can­cers, in­clud­ing acute lym­phoblas­tic leukemia (ALL).

Re­search so far sug­gests that re­sis­tance to CAR-T ther­a­pies is re­lat­ed to the loss of CD19. When CD19 dis­ap­pears from leukemic cells, they be­come in­vis­i­ble to CAR-T ther­a­pies, not­ed the study’s co-se­nior au­thor Mar­co Ruel­la, an as­sis­tant pro­fes­sor of hema­tol­ogy-on­col­o­gy at the Uni­ver­si­ty of Penn­syl­va­nia, in an in­ter­view with End­points News.

“That ex­plains maybe half of the re­laps­es in leukemia and maybe a third in lym­phoma — so there is still a vast ma­jor­i­ty of pa­tients where we sim­ply don’t know what’s go­ing on,” he said.

An­oth­er fac­tor dri­ving re­sis­tance was dys­func­tion­al T cells, he added. “What we are hy­poth­e­siz­ing here is that there can be a third mech­a­nism…that even in the pres­ence of CD19 those leukemic cells are un­able to die when they are trig­gered by CAR-T.”

“The con­stant pres­ence of the leukemic cells that ba­si­cal­ly can­not die — they’re sort of high­landers — caus­es dys­func­tion in the T-cells. To start with — the CAR-T (cells) are okay — but then they keep try­ing to kill leukemic cells that in­trin­si­cal­ly can­not die, and then, over time, they be­come dys­func­tion­al.”

The find­ings were pub­lished on Thurs­day in Can­cer Dis­cov­ery, a jour­nal of the Amer­i­can As­so­ci­a­tion for Can­cer Re­search.

In the Penn study, re­searchers per­formed a genome-wide CRISPR/Cas9-based screen of an ALL cell line to iso­late path­ways as­so­ci­at­ed with re­sis­tance. Cells were edit­ed for loss of func­tion of sin­gle genes and com­bined with CAR-T cells for 24 hours to iden­ti­fy the path­way dri­ving the pri­ma­ry re­sis­tance. The in vit­ro da­ta showed that in the ALL cells that re­sist­ed the CAR-T at­tack, there was a short­age of genes in­volved in ac­ti­vat­ing the cell death path­way and a spike in genes nec­es­sary for evad­ing the cell death path­way.

In­stead of in­ter­ro­gat­ing sam­ples from pa­tients that have failed to ben­e­fit from CAR-T ther­a­pies, the plan was to mod­el a genome-wide re­sis­tance mech­a­nism and then con­firm it in pa­tients. Many pa­tients are now be­ing treat­ed with CAR-Ts, but still, the num­bers are lim­it­ed — so this ap­proach was used to dis­cov­er aber­ra­tions that the lim­it­ed num­ber of pa­tient sam­ples would not be pow­ered to iden­ti­fy, Ruel­la said.

“We start­ed with an un­bi­ased genome-wide ap­proach to study re­sis­tance and we saw that the new CRISPR/Cas9 genome knock­out li­braries were per­fect be­cause they would al­low you to ex­plore knock­outs in the whole genome and in­ter­ro­gate it for re­sis­tance to CAR-T.”

The find­ings were am­pli­fied in an­i­mal mod­els. The re­searchers then tried to make sense of the re­sults by us­ing pe­di­atric pa­tient sam­ples from pre­vi­ous CAR-T tri­als by an­a­lyz­ing the genes in leukemia cells and in T cells — pre- and post-in­fu­sion — from re­spon­ders and non-re­spon­ders. The da­ta were stark: pre­vi­ous­ly iden­ti­fied sig­nal­ing path­ways in can­cer cells were di­rect­ly as­so­ci­at­ed with re­spons­es to CAR ther­a­py, sug­gest­ing that death re­cep­tor sig­nal­ing is a key reg­u­la­tor of pri­ma­ry re­sis­tance to CAR T cell ther­a­py in ALL, the au­thors con­clud­ed.

“This mech­a­nism ap­pears to re­ly on two phas­es: an ini­tial re­sis­tance to death re­cep­tor-dri­ven killing, fol­lowed by an anti­gen-dri­ven, pro­gres­sive im­pair­ment in CAR-T cell func­tion. To­geth­er this leads to CAR T cell fail­ure that per­pet­u­ates dis­ease pro­gres­sion,” they wrote.

De­spite their abun­dant promise, the adop­tion of CAR-T ther­a­pies — No­var­tis’ Kym­ri­ah and Gilead’s Yescar­ta — has un­der­whelmed ini­tial ex­pec­ta­tions.

The up­take of Kym­ri­ah was plagued by man­u­fac­tur­ing prob­lems, and de­spite No­var­tis’ at­tempt to ex­pand its ca­pac­i­ty, sales con­tin­ue to dis­ap­point com­mer­cial­ly, giv­ing Yescar­ta an edge in the mar­ket. Mean­while, big side ef­fects — no­tably life-threat­en­ing episodes of cy­tokine re­lease syn­drome and neu­ro­tox­i­c­i­ty — as well as the ther­a­pies’ ex­pen­sive price tags have al­so lim­it­ed their use. Oth­er drug de­vel­op­ers have tak­en note of these con­straints and are de­vel­op­ing off-the-shelf CAR-T ther­a­pies, de­signed to smoothen man­u­fac­tur­ing com­plex­i­ties by us­ing healthy donor cells.

But the team at Penn cau­tioned that the prac­tice may not nec­es­sar­i­ly help the sub­set of pa­tients whose can­cer cells car­ry this pro­por­tion of un­fa­vor­able genes.

“A pos­si­ble im­pli­ca­tion of our ob­ser­va­tions is that the use of healthy donor (i.e. al­lo­gene­ic donor or “uni­ver­sal” donor) T cells as a sub­strate for CAR T cell man­u­fac­tur­ing may face the same bar­ri­ers as au­tol­o­gous prod­ucts,” the au­thors wrote. “Un­der­stand­ing how in­trin­sic and ac­quired T cell dys­func­tion co­op­er­ate to cause ther­a­peu­tic fail­ure will be crit­i­cal to the de­sign of the next gen­er­a­tion of cel­lu­lar ther­a­pies.”

M&A: a crit­i­cal dri­ver for sus­tain­able top-line growth in health­care

2021 saw a record $600B in healthcare M&A activity. In 2022, there is an anticipated slowdown in activity, however, M&A prospects remain strong in the medium to long-term. What are future growth drivers for the healthcare sector? Where might we see innovations that drive M&A? RBC’s Andrew Callaway, Global Head, Healthcare Investment Banking discusses with Vito Sperduto, Global Co-Head, M&A.

Abortion-rights protesters regroup and protest following Supreme Court's decision to overturn Roe v. Wade. (AP Photo/Gemunu Amarasinghe)

Fol­low­ing SCO­TUS de­ci­sion to over­turn abor­tion pro­tec­tions, AG Gar­land says states can't ban the abor­tion pill

Following the Supreme Court’s historic decision on Friday to overturn Americans’ constitutional right to an abortion after almost 50 years, Attorney General Merrick Garland sought to somewhat reassure women that states will not be able to ban the prescription drug sometimes used for abortions.

Following the decision, the New England Journal of Medicine also published an editorial strongly condemning the reversal, saying it “serves American families poorly, putting their health, safety, finances, and futures at risk.”

AstraZeneca's new Evusheld direct to consumer campaign aims to reach more immunocompromised patients.

As­traZeneca de­buts first con­sumer cam­paign for its Covid-19 pro­phy­lac­tic Evusheld — and a first for EUA drugs

AstraZeneca’s first consumer ad for Evusheld is also a first for drugs that have been granted emergency use authorizations during the pandemic.

The first DTC ad for a medicine under emergency approval, the Evusheld campaign launching this week aims to raise awareness among immunocompromised patients — and spur more use.

Evusheld nabbed emergency authorization in December, however, despite millions of immunocompromised people looking for a solution and now more widespread availability of the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Yong Dai, Frontera Therapeutics CEO

Scoop: Lit­tle-known Or­biMed-backed biotech clos­es $160M round to start gene ther­a­py tri­al

Frontera Therapeutics, a China and US biotech, has closed a $160 million Series B and received regulatory clearance to test its first gene therapy stateside, Endpoints News has learned.

Led by the largest shareholder, OrbiMed, the biotech has secured $195 million total since its September 2019 founding, according to an email reviewed by Endpoints. The lead AAV gene therapy program is for an undisclosed rare eye disease, according to the source.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Sanofi, GSK tout 72% Omi­cron ef­fi­ca­cy in PhI­II tri­al of next-gen, bi­va­lent shot — with an eye to year-end roll­out

Sometimes, being late can give you an advantage.

That’s what Sanofi and GSK are trying to say as the Big Pharma partners report positive results from a late-stage trial of their next-gen bivalent Covid-19 vaccine, which was designed to protect against both the original strain of the SARS-CoV-2 virus and the Beta variant. Specifically, against Omicron, they note, the vaccine delivered 72% efficacy in all adults and 93.2% in those previously infected.

Matt Kapusta, uniQure CEO

In trou­bled Hunt­ing­ton’s space, uniQure’s gene ther­a­py shows ear­ly promise

In randomized clinical trial data from a small number of patients, Dutch biotech uniQure shared that its gene therapy for Huntington’s disease seems to reduce the amount of the mutant protein responsible for the disease over the course of a year.

In seven patients with early-stage Huntington’s — four who got the treatment and three who got a placebo — mutant huntingtin protein levels in the cerebrospinal fluid decreased by an average of just over 50% in patients who got the gene therapy compared to around a 17% drop in patients who got the placebo after a year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

John Leonard, Intellia CEO

In­tel­li­a's CRISPR pro­gram that ed­its genes di­rect­ly in pa­tients shows dura­bil­i­ty in AT­TR amy­loi­do­sis

The first in vivo CRISPR/Cas9 gene editing program has some new durability data showing sustained reduction of a toxic protein in ATTR amyloidosis at all four dose levels in a small 15-patient study.

Intellia Therapeutics presented the much-anticipated data for its Regeneron-collaborated NTLA-2001 Friday morning, adding to the initial Phase I results it first delivered almost a year ago to the day.

De­spite a slow start to the year for deals, PwC pre­dicts a flur­ry of ac­tiv­i­ty com­ing up

Despite whispers of a busy year for M&A, deal activity in the pharma space is actually down 30% on a semi-annualized basis, according to PwC’s latest report on deal activity. But don’t rule out larger deals in the second half of the year, the consultants said.

PwC pharmaceutical and life sciences consulting solutions leader Glenn Hunzinger expects to see Big Pharma companies picking up earlier stage companies to try and fill pipeline gaps ahead of a slew of big patent cliffs. Though a bear market continues to maul the biotech sector, Hunzinger said recent deals indicate that pharma companies are still paying above current trading prices.

Joe Wiley, Amryt Pharma CEO

Am­ryt Phar­ma sub­mits a for­mal dis­pute res­o­lu­tion to the FDA over re­ject­ed skin dis­ease drug

The story of Amryt Pharma’s candidate for the genetic skin condition epidermolysis bullosa, or EB, will soon enter another chapter.

After the Irish drugmaker’s candidate, dubbed Oleogel-S10 and marketed as Filsuvez, was handed a CRL earlier this year, the company announced in a press release that it plans to submit a formal dispute resolution request for the company’s NDA for Oleogel-S10.